基本情報
- CAS
98418-47-4- 標準SMILES
COCCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)CCC(=O)O- InChIKey
RGHAZVBIOOEVQX-UHFFFAOYSA-N- 分子式
- C34H56N2O10
- 平均分子量
- 652.8 g/mol
- 単同位体質量
- 652.39349599
概要
Metoprolol succinate is an alcohol and a member of phenols.
名称と識別子
- 優先名称
- Metoprolol Succinate
- IUPAC
- butanedioic acid;bis(1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol)
- 現地名
- こはく酸メトプロロール
- 英語名
- Metroprolol succinate
- 分子式
- 2C15H25NO3.C4H6O4
- 分子量
- 652.82
名称と別名
Metoprolol succinate98418-47-4SelozokToprol XLSeloken-ZOKMetoprolol hemisuccinateH 93/26 succinateTOPROL-XLDTXSID9048726TH25PD4CCBDTXCID6028652KAPSPARGO
名称をさらに表示
こはく酸メトプロロールrolol succinateMaetaprolol succinateMETOPROLOL SUCCINATE USPMetoprolol succinate BaseMetoprolol Succinate (200 mg)Metoprolol Succinate (ToprolX)
Metoprolol Succinate ERRefChem:55626KAPSPARGO SPRINKLEMetoprolol Succinate E/rMetoprolol Succinate ER TabletsMetoprolol Succinate Extended-releaseToprolMetroprolol succinate
データベース識別子
- CAS
98418-47-4- PubChem CID
- 62937
- DTXSID
DTXSID9048726- ChEMBL
CHEMBL2356097- ChEBI
CHEBI:6905- UNII
- TH25PD4CCB
- EC Number
物性
構造計算による物性
- 極性表面積
- 176 Ų
- 水素結合供与体数
- 6
- 水素結合受容体数
- 12
- 回転可能結合数
- 21
- 重原子数
- 46
- 形式電荷
- 0
- 複雑度
- 308
実験および物理化学的性質
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiarrhythmics
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
物理化学的性質
- 融点
- 136 · 136-138°C
- 貯蔵温度
- Hygroscopic, Refrigerator, under inert atmosphere
- 溶解性
- 水に易溶、メタノールに可溶、エタノール(96%)に難溶、酢酸エチルに極難溶。
- 外見
- Solid
- 色
- ホワイトからオフホワイト
- 安定性
- 吸湿性
- InChI
- InChI=1S/2C15H25NO3.C4H6O4/c2*1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3;5-3(6)1-2-4(7)8/h2*4-7,12,14,16-17H,8-11H2,1-3H3;1-2H2,(H,5,6)(H,7,8)
- InChIKey
- RGHAZVBIOOEVQX-UHFFFAOYSA-N
- SMILES
- C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1.C(C(=O)O)CC(=O)O.C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1
化学的性質
化学的特性White or almost white, crystalline powder.
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Danger
H302 (11.5%): Harmful if swallowed [Warning Acute toxicity, oral]
P260, P264, P270, P273, P301+P317, P308+P316, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 52 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Hazard Classes and CategoriesAcute Tox. 4 (11.5%)
毒性情報
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Metoprolol succinate
Ambiguous-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
安全データ
- hs_code
- 2922190900
化学と産業
薬理情報
FDA Pharmacological Classification
METOPROLOL SUCCINATE
Adrenergic beta-Antagonists [MoA]; beta-Adrenergic Blocker [EPC]
METOPROLOL SUCCINATE ER
beta-Adrenergic Blocker [EPC]; Adrenergic beta-Antagonists [MoA]
METOPROLOL SUCCINATE ER TABLETS
Adrenergic beta-Antagonists [MoA]; beta-Adrenergic Blocker [EPC]
MeSH Pharmacological Classification
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.
Drugs that bind to and block the activation of ADRENERGIC BETA-1 RECEPTORS.
応用分野
来歴Metoprolol Succinate, the world's first Beta-1 Selective Receptor blocker, was developed by AstraZeneca and first launched in 1992. It is commonly used in clinical practice to treat hypertension, angina pectoris, and stable chronic heart failure with impaired left ventricular systolic function.Metoprolol was first developed in 1969 at Hassle Laboratories in Sweden. As a selective beta-1 adrenergic receptor blocker, it binds to beta-1 receptors to antagonize the effects of neurotransmitters and catecholamines on beta receptors. This action increases vascular smooth muscle sensitivity to vasoactive mediators and inhibits renin secretion. Clinically, it is used to treat hypertension, angina pectoris, and heart failure.
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…